Aytu BioPharma, Inc. (NASDAQ:AYTU) Short Interest Down 6.0% in July

Aytu BioPharma, Inc. (NASDAQ:AYTU) was the target of a significant decrease in short interest in the month of July. As of July 31st, there was short interest totalling 372,500 shares, a decrease of 6.0% from the July 15th total of 396,200 shares. Based on an average trading volume of 22,200 shares, the short-interest ratio is presently 16.8 days. Currently, 6.5% of the shares of the stock are sold short.

Aytu BioPharma Stock Down 0.4 %

NASDAQ:AYTU opened at $2.63 on Tuesday. Aytu BioPharma has a 52 week low of $1.52 and a 52 week high of $3.50. The stock’s 50-day moving average price is $2.75 and its 200-day moving average price is $2.92. The stock has a market capitalization of $15.71 million, a PE ratio of -1.00 and a beta of -1.41.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aytu BioPharma stock. Armistice Capital LLC acquired a new position in shares of Aytu BioPharma, Inc. (NASDAQ:AYTU) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 252,000 shares of the company’s stock, valued at approximately $736,000. Armistice Capital LLC owned 4.22% of Aytu BioPharma as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 33.49% of the company’s stock.

About Aytu BioPharma

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.